Last update :
08/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Carboplatin  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Acoplasic Mexico
Axicarb Germany
Balidon Colombia
Blastocarb Chile, Colombia, Mexico, Peru
Boplatex Colombia, Ecuador, Mexico
Carbip Mexico
Carbodex Turkey
Carboeen India
Carbokebir Argentina
Carbokem India
Carbol Peru
Carbomedac Sweden
Carboplat Argentina, Germany, Mexico
Carboplatin Australia, Austria, Belgium, Brazil, Canada, Denmark, Egypt, Finland, Greece, Iceland, India, Iran, Ireland, Luxembourg, Morocco, New Zealand, Saudi Arabia, United States of America
Carboplatine France, Morocco, Switzerland
Carboplatino Argentina, Chile, Colombia, Spain
Carbosin Belgium, Egypt, Greece, Malaysia
Cycloplatin Hungary, Poland
Emorzym Greece
Megaplatin Greece
Nuvaplast Mexico
Paraplatin Austria, Belgium, Denmark, Finland, Great Britain, Greece, Hungary, Italy, Luxembourg, Mexico, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, United Arab Emirates, United States of America
Paraplatine France, Morocco, Tunisia
Platinwas Spain
Stability of mixtures   Injection   Stability of mixtures : Carboplatin     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 0,5 mg/ml
Injection   Carboplatin   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Light 57
Level of evidence A+
Glass Glucose 5% 2 mg/ml
Injection   Carboplatin   
Injection   Acetyl L-carnitine 15 mg/ml
25°C
4 Hour
3277
Level of evidence A+
Glass Glucose 5% 2,5 mg/ml
Injection   Carboplatin   
Injection   Palonosetron hydrochloride 25 µg/ml
?
4 Hour
Not specified 1950
Level of evidence A+
Polyolefine NaCl 0,9% or Glucose 5% 2 mg/ml
Injection   Carboplatin   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
23°C
24 Hour
Not specified 872
Level of evidence B+
Polyolefine NaCl 0,9% or Glucose 5% 2 mg/ml
Injection   Carboplatin   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
32°C
24 Hour
Not specified 872
Level of evidence B+
Polyolefine NaCl 0,9% or Glucose 5% 2 mg/ml
Injection   Carboplatin   
Injection   Paclitaxel 0,3 & 1,2 mg/ml
4°C
24 Hour
Protect from light 872
Level of evidence B+
Not specified NaCl 0,9% or Glucose 5% 0,45 mg/ml
Injection   Carboplatin   
Injection   Topotecan 0,028 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
  Mentions Légales